Table 1 Baseline characteristics of male and female breast cancer
Demographics | Total(n =199 ) | Male(n =106 ) | Female(n = 93) | χ2 | P Value* |
|---|---|---|---|---|---|
Age | |||||
<60 years | 81 | 28 (26.42%) | 53 (56.99%) | 19.186 | 0.000* |
≥ 60 years | 118 | 78 (73.58%) | 40 (43.01%) | ||
Laterality | |||||
Right | 97 | 46 (43.40%) | 51 (54.84%) | 2.660 | 0.264 |
Left | 100 | 59 (55.66%) | 41 (44.09%) | ||
Other | 2 | 1 (0.94%) | 1 (1.08%) | ||
Maximum tumor diameter | |||||
<2 | 52 | 32 (30.19%) | 20 (21.51%) | 4.117 | 0.128 |
≥ 2 | 139 | 72 (67.92%) | 67 (72.04%) | ||
Other | 8 | 2 (1.89%) | 6 (6.45%) | ||
Lymph node metastases | |||||
Yes | 73 | 42 (39.62%) | 31 (33.33%) | 0.8448 | 0.358 |
No | 126 | 64 (60.38%) | 62 (66.67%) | ||
HER2 | |||||
0 | 48 | 23(21.69%) | 25 (26.88%) | 6.675 | 0.036* |
Low | 120 | 72 (67.93%) | 48 (51.61%) | ||
Positive | 31 | 11 (10.38%) | 20 (21.51%) | ||
HER2 | |||||
0 | 48 | 23(21.70%) | 25 (26.88%) | 16.483 | 0.002* |
1+ | 55 | 27 (24.47%) | 28 (30.11%) | ||
2 + ISH - | 65 | 45 (42.45%) | 20 (21.51%) | ||
2 + ISH + | 9 | 6(5.66%) | 3 (3.23%) | ||
3+ | 22 | 5(4.72%) | 17 (18.28%) | ||
Estrogen Receptor, ER | |||||
Negative | 27 | 7 (6.60%) | 16 (17.20%) | 5.446 | 0.026* |
Positive | 172 | 99 (93.40%) | 77 (82.80%) | ||
Progestogen Receptor, PR | |||||
Negative | 32 | 8 (7.55%) | 19 (20.43%) | 7.011 | 0.008* |
Positive | 167 | 98(92.45%) | 74 (79.57%) | ||
Ki-67 | |||||
<14% | 34 | 19 (17.92%) | 15 (16.13%) | 0.113 | 0.737 |
≥ 14% | 165 | 87 (82.08%) | 78 (83.87%) | ||